GZR-33
Phase 1Small molecule
GZR-33 is one of 13 small molecule programs targeting LAM. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
12 competitors in LAM
#DrugCompanyPhaseTrials
1Kesimpta
NovartisApproved
Rituxan
RochePhase 2
Budesonide/formoterol
AstraZenecaPhase 3
Humira
Boehringer IngelheimPhase 2
Kineret
AmgenPhase 2
Cosentyx
Johnson & JohnsonPhase 2
Roactemra
KKarolinska Institutet
Phase 2
Stelara
BBiocon Biologics UK PLC
Phase 2
Colesevelam Hcl
Daiichi SankyoPreclinical
NAGLAZYME
BioMarin PharmaceuticalPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GZR-33. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- GGan and Lee Pharmaceuticals, USA